239 related articles for article (PubMed ID: 33058300)
1. Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.
Li XJ; Li QL; Ju LG; Zhao C; Zhao LS; Du JW; Wang Y; Zheng L; Song BL; Li LY; Li L; Wu M
Hepatology; 2021 May; 73(5):1797-1815. PubMed ID: 33058300
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase Setd2 is critical for the proliferation and differentiation of myoblasts.
Yi X; Tao Y; Lin X; Dai Y; Yang T; Yue X; Jiang X; Li X; Jiang DS; Andrade KC; Chang J
Biochim Biophys Acta Mol Cell Res; 2017 Apr; 1864(4):697-707. PubMed ID: 28130125
[TBL] [Abstract][Full Text] [Related]
4. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2.
Li H; An J; Wu M; Zheng Q; Gui X; Li T; Pu H; Lu D
Oncotarget; 2015 Sep; 6(29):27847-64. PubMed ID: 26172293
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between the H3K36me3 and H4K16ac histone epigenetic marks in DNA double-strand break repair.
Li L; Wang Y
J Biol Chem; 2017 Jul; 292(28):11951-11959. PubMed ID: 28546430
[TBL] [Abstract][Full Text] [Related]
7. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
10. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
[TBL] [Abstract][Full Text] [Related]
11. The histone methyltransferase SETD2 is required for expression of acrosin-binding protein 1 and protamines and essential for spermiogenesis in mice.
Zuo X; Rong B; Li L; Lv R; Lan F; Tong MH
J Biol Chem; 2018 Jun; 293(24):9188-9197. PubMed ID: 29716999
[TBL] [Abstract][Full Text] [Related]
12. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
13. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells.
Wang L; Niu N; Li L; Shao R; Ouyang H; Zou W
PLoS Biol; 2018 Nov; 16(11):e2006522. PubMed ID: 30422989
[TBL] [Abstract][Full Text] [Related]
14. Systematic
Walter DM; Venancio OS; Buza EL; Tobias JW; Deshpande C; Gudiel AA; Kim-Kiselak C; Cicchini M; Yates TJ; Feldser DM
Cancer Res; 2017 Apr; 77(7):1719-1729. PubMed ID: 28202515
[TBL] [Abstract][Full Text] [Related]
15. SETD2 deficiency promotes renal fibrosis through the TGF-β/Smad signalling pathway in the absence of VHL.
Liu C; Ni L; Li X; Rao H; Feng W; Zhu Y; Zhang W; Ma C; Xu Y; Gui L; Wang Z; Aji R; Xu J; Gao WQ; Li L
Clin Transl Med; 2023 Nov; 13(11):e1468. PubMed ID: 37933774
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription.
Carvalho S; Raposo AC; Martins FB; Grosso AR; Sridhara SC; Rino J; Carmo-Fonseca M; de Almeida SF
Nucleic Acids Res; 2013 Mar; 41(5):2881-93. PubMed ID: 23325844
[TBL] [Abstract][Full Text] [Related]
17. Regulation of SETD2 stability is important for the fidelity of H3K36me3 deposition.
Bhattacharya S; Workman JL
Epigenetics Chromatin; 2020 Oct; 13(1):40. PubMed ID: 33023640
[TBL] [Abstract][Full Text] [Related]
18. MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis.
Podrini C; Koffas A; Chokshi S; Vinciguerra M; Lelliott CJ; White JK; Adissu HA; Williams R; Greco A
FASEB J; 2015 May; 29(5):1676-87. PubMed ID: 25526730
[TBL] [Abstract][Full Text] [Related]
19. H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm.
Zhang Y; Xie S; Zhou Y; Xie Y; Liu P; Sun M; Xiao H; Jin Y; Sun X; Chen Z; Huang Q; Chen S
Cell Rep; 2014 Sep; 8(6):1989-2002. PubMed ID: 25242323
[TBL] [Abstract][Full Text] [Related]
20. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
